Track topics on Twitter Track topics that are important to you
The spinoff-turned-Sanofi-company could pay more than $100 million to Oxford BioMedica for lentiviral vector production.
Original Article: Bioverativ taps new manufacturer as it steps out of Biogen's shadowNEXT ARTICLE
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...